Harmony Advances First Human Study of Orexin 2 Agonist
BP1.15205 enters phase 1 testing as Harmony positions the selective OX2R agonist to broaden treatment choices for narcolepsy and other hypersomnolence disorders.
Read More
Author: Sleep Review Staff
Newly Launched Acoustic Headband Aims to Harmonize Brainwaves for Better Sleep
Spatial Sleep uses facial-scan–based sound and vibration profiles to deliver a customized, nonpharmacologic approach to calming the mind at bedtime.
Read More
Bidding War Erupts Over Narcolepsy Drug Manufacturer Avadel
An unsolicited offer from Lundbeck threatens to derail Alkermes’ acquisition as competing bids emerge for LUMRYZ maker.
Read More
Shanghai Company Develops Aligner That Treats Sleep Apnea and Straightens Teeth
Not yet available in the United States, Smartee Sleep Aligners are designed to correct anterior teeth during the day and maintain airway patency at night.
Read More
Alkermes Shares Phase 2 Results of Orexin 2 Receptor Agonist in Narcolepsy Type 2
Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor agonist in phase 2 development for the treatment of narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Read More